Acurx Pharmaceuticals, Inc.

The microbiome of patients experiencing recurrent CDI is frequently dominated by overgrowths of Enterococcus species This study evaluated the in vitro bactericidal and molecular efficacy of ibezapolstat (IBZ), vancomycin (VAN), and fidaxomicin (FDX) against C. difficile and Enterococcus in standalone and complex co-culture environments These findings demonstrate that Enterococcus creates a protective microenvironment that actively impairs C.

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in C. difficile Infection (CDI) As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA STATEN ISLAND, N.Y.

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript

STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2026.